Aura Biosciences, Inc.

NasdaqGM:AURA Stock Report

Market Cap: US$378.9m

Aura Biosciences Management

Management criteria checks 1/4

Aura Biosciences' CEO is Eli de los Pinos, appointed in Jan 2007, has a tenure of 17.33 years. total yearly compensation is $4.04M, comprised of 14.5% salary and 85.5% bonuses, including company stock and options. directly owns 0.33% of the company’s shares, worth $1.26M. The average tenure of the management team and the board of directors is 1.3 years and 3.3 years respectively.

Key information

Eli de los Pinos

Chief executive officer

US$4.0m

Total compensation

CEO salary percentage14.5%
CEO tenure17.3yrs
CEO ownership0.3%
Management average tenure1.3yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Oct 03
We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Mar 28
Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Oct 01
We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Aura gains as JMP starts with Bullish view citing treatment platform

Jul 19

Aura Biosciences' AU-011 gets FDA fast-track status for bladder cancer

Jun 30

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Apr 10
Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

CEO Compensation Analysis

How has Eli de los Pinos's remuneration changed compared to Aura Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$4mUS$586k

-US$76m

Sep 30 2023n/an/a

-US$71m

Jun 30 2023n/an/a

-US$68m

Mar 31 2023n/an/a

-US$63m

Dec 31 2022US$795kUS$555k

-US$59m

Sep 30 2022n/an/a

-US$55m

Jun 30 2022n/an/a

-US$52m

Mar 31 2022n/an/a

-US$51m

Dec 31 2021US$7mUS$432k

-US$46m

Sep 30 2021n/an/a

-US$40m

Jun 30 2021n/an/a

-US$33m

Mar 31 2021n/an/a

-US$29m

Dec 31 2020US$1mUS$395k

-US$30m

Compensation vs Market: Eli's total compensation ($USD4.04M) is above average for companies of similar size in the US market ($USD2.41M).

Compensation vs Earnings: Eli's compensation has increased whilst the company is unprofitable.

CEO

Eli de los Pinos (49 yo)

17.3yrs

Tenure

US$4,044,598

Compensation

Dr. Elisabet de los Pinos, also known as Eli, Ph D., is the Founder of Aura Biosciences, Inc. and serves as its Chief Executive Officer and President. Dr. de los Pinos has over ten years of experience in O...

Leadership Team

NamePositionTenureCompensationOwnership
Elisabet de los Pinos
Founder17.3yrsUS$4.04m0.33%
$ 1.3m
Julie Feder
Chief Financial Officer5.8yrsUS$1.86m0%
$ 0
Mark Plavsic
Chief Technology Officerless than a yearno data0.26%
$ 983.1k
Conor Kilroy
General Counsel & Secretaryless than a yearno datano data
Patrick Nealon
Senior Vice President of Clinical Development Operations1.3yrsno datano data
Bruce Brown
Senior VP & Therapeutic Area Head of Urologic Oncology1.3yrsno datano data
Anthony Daniels
Therapeutic Area Head of Ocular Oncology1.3yrsno datano data
Richard Mountfield
Senior Vice President of Regulatory Affairs & Quality1.3yrsno datano data
Jill Hopkins
Chief Medical Officer & President of Research and Developmentless than a yearno datano data

1.3yrs

Average Tenure

52yo

Average Age

Experienced Management: AURA's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Elisabet de los Pinos
Founderno dataUS$4.04m0.33%
$ 1.3m
Rajesh Parekh
Independent Director9.3yrsUS$188.38k0%
$ 0
Evangelos Gragoudas
Scientific & Clinical Advisorno datano datano data
Sapna Srivastava
Independent Director3yrsUS$203.38k0%
$ 0
Jay Duker
Scientific & Clinical Advisorno datano datano data
Antony Mattessich
Independent Director2.7yrsUS$260.78k0%
$ 0
Giovanni Mariggi
Independent Director5.1yrsno datano data
Richard Carvajal
Scientific & Clinical Advisorno datano datano data
David Johnson
Independent Chairman of the Board3.3yrsUS$289.28k0.86%
$ 3.3m
Arun Singh
Scientific & Clinical Advisorno datano datano data
Carol Shields
Scientific & Clinical Advisorno datano datano data
Brian Marr
Scientific & Clinical Advisorno datano datano data

3.3yrs

Average Tenure

55yo

Average Age

Experienced Board: AURA's board of directors are considered experienced (3.3 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.